CD68 and acute myeloid leukemia: As CD68+ populations with lower frequency of leukemic mutations were present in the NPM1+ AML 10-patient cohort24 (Figure S3H), we suggest that another biomarker should be included to deplete CD68+ cells of the healthy hematopoietic system from RECs.